Art. -Nr.: HY-19350

BML-210

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

BML-210 is a potent HDAC inhibitor. BML-210 can inhibit the HDAC4-VP16-driven reporter signal with an apparent IC₅₀ of ∼5 µM. BML-210 has a specific disruptive effect on the HDAC4:MEF2 interaction. BML-210 causes an increase in the G0/G1 phase. BML-210 induces apoptosis and displays antitumour activities in orthotopic mammary tumours in mice.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.04%
CAS. Nr.: 537034-17-6
Formel: C₂₀H₂₅N₃O₂
Molecular Weight:339.43

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

BML-210 Chemical Structure

CAS. Nr.: 537034-17-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

HDAC4:MEF2

Alle HDAC Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	IC₅₀	87 μM Compound: 4c, BML-210	Inhibition of HDAC in human HeLa cell extract by fluorescence plate reader assay Inhibition of HDAC in human HeLa cell extract by fluorescence plate reader assay	[PMID: 16921367]
MV4-11	IC₅₀	7244 nM Compound: 4	Antiproliferative activity against human MV4-11 cells Antiproliferative activity against human MV4-11 cells	[PMID: 35580726]

In Vitro

BML-210 (10, 20 μM; 24, 48 hours) inhibits cell proliferation and growth inhibition of NB4 cells^[2].
BML-210 (10, 20 μM; 24, 48 hours) causes a decrease in the proportion of NB4 cells in the S phase and an increase in the G0/G1 phase^[2].
BML-210 (10, 20 μM; 24, 48 hours) causes cytotoxic effects on NB4 cells at 20 μM. BML-210 at a dose of 10 μM induces apoptotic cell death^[2].
BML-210 (10, 20 μM; 24, 48 hours) inhibits HDAC Expression and Activity in NB4 Cells^[2].
BML-210 (1.0 μM; for 48 h) causes higher expression levels differential expressed genes (DEGs) in mouse EO771 cells^[3].
BML-210 does not reduce the expression of HDAC4-VP16^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

NB4 cells
Concentration:

10, 20 μM
Incubation Time:

24, 48 hours
Result:

Inhibited cell proliferation and growth inhibition of NB4 cells in a dose- and time-dependent manner.

Cell Cycle Analysis^[2]

Cell Line:

NB4 cells
Concentration:

10, 20 μM
Incubation Time:

24, 48 hours
Result:

Caused a decrease in the proportion of NB4 cells in the S phase and an increase in the G0/G1 phase.
Caused an increase in the G0/G1 phase up to 70% at 24 and 48 h with 10 μM.

Cell Cytotoxicity Assay^[2]

Cell Line:

NB4 cells
Concentration:

10, 20 μM
Incubation Time:

24, 48 hours
Result:

Caused cytotoxic effects on NB4 cells in a dose- and time-dependent manner.

Apoptosis Analysis^[2]

Cell Line:

NB4 cells
Concentration:

10, 20 μM
Incubation Time:

24, 48 hours
Result:

At a dose of 10 μM induced apoptotic cell death.

Western Blot Analysis^[2]

Cell Line:

NB4 cells
Concentration:

10, 20 μM
Incubation Time:

24, 48 hours
Result:

At 10 μM dose inhibited HDAC1 gene expression up to 36% after 48 h of treatment Inhibited HDAC expression up to 74% at 8 h point at 20 μM.
Had very low effect on HDAC 2 and HDAC 3 expression.

In Vivo

BML-210 (20 mg/kg; IP; three times per week for two weeks) notably suppresses the tumour growth and weight. BML-210 has no effect on tumour growth and weight in the immune-deficient nude (Nu/J) mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female C57BL/6 mice with mouse breast cancer EO771 cells^[3]
Dosage:

20 mg/kg
Administration:

IP; three times per week for two weeks
Result:

Notably suppressed the tumour growth and weight.

Chemical Information

CAS. Nr. 537034-17-6
Appearance Solid
Molecular Weight 339.43
Formel C₂₀H₂₅N₃O₂
Color White to off-white
SMILES

O=C(NC1=CC=CC=C1N)CCCCCCC(NC2=CC=CC=C2)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Transl Stroke Res

HDAC9 Deficiency Upregulates cGMP-dependent Kinase II to Mitigate Neuronal Apoptosis in Ischemic Stroke. [Abstract]

2025 Jun;16(3):868-881. PMID: 38940872

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 30 mg/mL (88.38 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9461 mL

14.7306 mL

29.4612 mL

5 mM

0.5892 mL

2.9461 mL

5.8922 mL

10 mM

0.2946 mL

1.4731 mL

2.9461 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (760 KB)
- English - EN (760 KB)
- Français - FR (760 KB)
- Deutsch - DE (760 KB)
- Norwegian - NO (760 KB)
- Español - ES (760 KB)
- Swedish - SV (760 KB)
- Italian - IT (760 KB)
- Korean - KR (760 KB)
- Portuguese - PT (760 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Nimanthi Jayathilaka, et al. Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2. Nucleic Acids Res. 2012 Jul; 40(12): 5378–5388.

[2]. Veronika Borutinskaite, et al. The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming. Int J Mol Sci. 2015 Aug; 16(8): 18252–18269.

[3]. Zhuolong Zhou, et al. An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity. Nat Biomed Eng. 2021 Nov;5(11):1320-1335. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9461 mL	14.7306 mL	29.4612 mL	73.6529 mL
	5 mM	0.5892 mL	2.9461 mL	5.8922 mL	14.7306 mL
	10 mM	0.2946 mL	1.4731 mL	2.9461 mL	7.3653 mL
	15 mM	0.1964 mL	0.9820 mL	1.9641 mL	4.9102 mL
	20 mM	0.1473 mL	0.7365 mL	1.4731 mL	3.6826 mL
	25 mM	0.1178 mL	0.5892 mL	1.1784 mL	2.9461 mL
	30 mM	0.0982 mL	0.4910 mL	0.9820 mL	2.4551 mL
	40 mM	0.0737 mL	0.3683 mL	0.7365 mL	1.8413 mL
	50 mM	0.0589 mL	0.2946 mL	0.5892 mL	1.4731 mL
	60 mM	0.0491 mL	0.2455 mL	0.4910 mL	1.2275 mL
	80 mM	0.0368 mL	0.1841 mL	0.3683 mL	0.9207 mL

Keywords

BML-210

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

BML-210

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Liver Cancer Compound Library

Osteogenesis Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) BML-210

Alle HDAC Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BML-210

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Liver Cancer Compound Library

Osteogenesis Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) BML-210

Alle HDAC Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BML-210 Related Classifications

HY-19350 Related Classifications